A: Dose of 25 mg: Blood concentration of sirolimus and
temsirolimus through-out one week. B: Dose 75 mg: Blood
concentration of sirolimus and temsirolimus through-out one weekReferences
Widmer N, Bardin C, Chatelut E,
Paci A, Beijnen J, Leveque D, et al. Review of therapeutic drug
monitoring of anticancer drugs part two–targeted therapies.
European journal of cancer 2014; 50: 2020-36.
Atkins MB, Hidalgo M, Stadler WM,
Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II
study of multiple dose levels of CCI-779, a novel mammalian target of
rapamycin kinase inhibitor, in patients with advanced refractory renal
cell carcinoma. J Clin Oncol 2004; 22: 909-18.
Kuhn JG, Chang SM, Wen PY,
Cloughesy TF, Greenberg H, Schiff D, et al. Pharmacokinetic and
tumor distribution characteristics of temsirolimus in patients with
recurrent malignant glioma. Clin Cancer Res 2007; 13: 7401-6.
Mai KT, Perkins DG, Collins JP.
Epithelioid cell variant of renal angiomyolipoma. Histopathology 1996;
28: 277-80.
Faraji H, Nguyen BN, Mai KT. Renal
epithelioid angiomyolipoma: a study of six cases and a meta-analytic
study. Development of criteria for screening the entity with
prognostic significance. Histopathology 2009; 55: 525-34.
Astrinidis A, Henske EP. Tuberous
sclerosis complex: linking growth and energy signaling pathways with
human disease. Oncogene 2005; 24: 7475-81.
Avgeris S, Fostira F, Vagena A,
Ninios Y, Delimitsou A, Vodicka R, et al. Mutational analysis
of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from
Greece. Sci Rep 2017; 7: 16697.
Tabernero J, Rojo F, Calvo E,
Burris H, Judson I, Hazell K, et al. Dose- and schedule-
dependent inhibition of the mammalian target of rapamycin pathway with
everolimus: a phase I tumor pharmacodynamic study in patients with
advanced solid tumors. J Clin Oncol 2008; 26: 1603-10.
Bissler JJ, McCormack FX, Young
LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for
angiomyolipoma in tuberous sclerosis complex or
lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-51.
Bissler JJ, Kingswood JC,
Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al.Everolimus for angiomyolipoma associated with tuberous sclerosis
complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre,
randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:
817-24.
Krueger DA, Northrup H. Tuberous
sclerosis complex surveillance and management: recommendations of the
2012 International Tuberous Sclerosis Complex Consensus Conference.
Pediatr Neurol 2013; 49: 255-65.
Pirson Y. Tuberous sclerosis
complex-associated kidney angiomyolipoma: from contemplation to
action. Nephrol Dial Transplant 2013; 28: 1680-5.